Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer.
blood biomarker
circulating biomarker
immune-checkpoint inhibitor
immunotherapy
liquid biopsy
lung cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
03 Dec 2020
03 Dec 2020
Historique:
received:
01
11
2020
revised:
30
11
2020
accepted:
01
12
2020
entrez:
8
12
2020
pubmed:
9
12
2020
medline:
9
12
2020
Statut:
epublish
Résumé
Immune checkpoint inhibitors are now a cornerstone of treatment for non-small cell lung cancer (NSCLC). Tissue-based assays, such as Programmed cell death protein 1 (PD-L1) expression or mismatch repair deficiency/microsatellite instability (MMRD/MSI) status, are approved as treatment drivers in various settings, and represent the main field of research in biomarkers for immunotherapy. Nonetheless, responses have been observed in patients with negative PD-L1 or low tumor mutational burden. Some aspects of biomarker use remain poorly understood and sub-optimal, in particular tumoral heterogeneity, time-evolving sampling, and the ability to detect patients who are unlikely to respond. Moreover, tumor biopsies offer little insight into the host's immune status. Circulating biomarkers offer an alternative non-invasive solution to address these pitfalls. Here, we summarize current knowledge on circulating biomarkers while using liquid biopsies in patients with lung cancer who receive treatment with immune checkpoint inhibitors, in terms of their potential as being predictive of outcome as well as their role in monitoring ongoing treatment. We address host biomarkers, notably circulating immune cells and soluble systemic immune and inflammatory markers, and also review tumor markers, including blood-based tumor mutational burden, circulating tumor cells, and circulating tumor DNA. Technical requirements are discussed along with the current limitations that are associated with these promising biomarkers.
Identifiants
pubmed: 33287347
pii: cancers12123625
doi: 10.3390/cancers12123625
pmc: PMC7761725
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Lung Cancer. 2018 Jun;120:108-112
pubmed: 29748004
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
J Natl Cancer Inst. 2014 May 29;106(6):dju124
pubmed: 24875653
Nat Commun. 2017 Feb 01;8:14381
pubmed: 28146145
Clin Cancer Res. 2019 Apr 1;25(7):2144-2154
pubmed: 30647082
Cancer Discov. 2020 Dec;10(12):1842-1853
pubmed: 32816849
Immunity. 2016 May 17;44(5):973-88
pubmed: 27192564
Cancer Immunol Immunother. 2013 Sep;62(9):1439-51
pubmed: 23760662
Nat Rev Clin Oncol. 2018 Dec;15(12):748-762
pubmed: 30361681
Medicine (Baltimore). 2018 Jan;97(3):e9617
pubmed: 29504990
Cell. 2017 Nov 2;171(4):934-949.e16
pubmed: 29033130
Sci Rep. 2019 Jul 12;9(1):10144
pubmed: 31300681
Oncotarget. 2017 Nov 30;8(67):112132-112144
pubmed: 29340117
JAMA Oncol. 2018 Mar 1;4(3):351-357
pubmed: 29327044
JAMA Oncol. 2019 May 1;5(5):696-702
pubmed: 30816954
Am J Respir Crit Care Med. 2019 Jan 15;199(2):243-246
pubmed: 30339766
J Thorac Oncol. 2019 Aug;14(8):1440-1446
pubmed: 30999110
Nat Med. 2019 Aug;25(8):1251-1259
pubmed: 31359002
Am J Respir Crit Care Med. 2018 Sep 15;198(6):777-787
pubmed: 29617574
Lancet Oncol. 2020 Oct;21(10):1353-1365
pubmed: 32919526
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Clin Cancer Res. 2020 Sep 4;:
pubmed: 32887723
Scand J Immunol. 2017 Nov;86(5):361-367
pubmed: 28930374
Proc Natl Acad Sci U S A. 2018 May 1;115(18):4749-4754
pubmed: 29654146
Clin Lung Cancer. 2018 Sep;19(5):410-417.e1
pubmed: 29859759
Cytokine. 2011 Nov;56(2):231-8
pubmed: 21733718
Exp Mol Med. 2019 Aug 9;51(8):1-13
pubmed: 31399559
Medicine (Baltimore). 2018 Sep;97(38):e12524
pubmed: 30235773
Leukemia. 2014 Dec;28(12):2367-75
pubmed: 24732592
Ann Oncol. 2017 Aug 1;28(8):1996-2001
pubmed: 28459943
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
EMBO J. 1992 Nov;11(11):3887-95
pubmed: 1396582
Ther Adv Med Oncol. 2018 Apr 07;10:1758835918768238
pubmed: 29662549
Nature. 2018 Aug;560(7718):382-386
pubmed: 30089911
Immunol Lett. 2012 Feb 29;142(1-2):78-82
pubmed: 22138406
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Clin Cancer Res. 2018 Apr 15;24(8):1872-1880
pubmed: 29330207
Ann N Y Acad Sci. 2011 Jan;1217:45-59
pubmed: 21276005
J Thorac Oncol. 2020 Sep;15(9):1449-1459
pubmed: 32389639
Oncotarget. 2017 Oct 24;8(60):101994-102005
pubmed: 29254220
Ann Oncol. 2017 Aug 1;28(8):1988-1995
pubmed: 28595336
J Thorac Oncol. 2019 Sep;14(9):e209
pubmed: 31445741
Lung Cancer. 2019 Oct;136:45-51
pubmed: 31437663
Nat Commun. 2018 Aug 10;9(1):3196
pubmed: 30097571
J Clin Oncol. 2019 Mar 1;37(7):537-546
pubmed: 30620668
J Immunol. 2000 May 15;164(10):5015-8
pubmed: 10799854
Hum Immunol. 2000 Oct;61(10):951-8
pubmed: 11082508
Thorac Cancer. 2015 Jul;6(4):534-8
pubmed: 26273411
JAMA Oncol. 2019 Jul 25;:
pubmed: 31343662
Hum Pathol. 2017 Aug;66:13-33
pubmed: 28694003
Ann N Y Acad Sci. 2014 Jun;1319:47-65
pubmed: 24965257
Nat Med. 2018 Sep;24(9):1441-1448
pubmed: 30082870
J Cancer Res Clin Oncol. 2010 Jan;136(1):35-45
pubmed: 19572148
Lung Cancer. 2017 Feb;104:1-6
pubmed: 28212990
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
Cancers (Basel). 2019 Jun 17;11(6):
pubmed: 31212989
Ann Oncol. 2019 Oct 1;30(10):1653-1659
pubmed: 31435660
J Mol Diagn. 2017 Jan;19(1):4-23
pubmed: 27993330
Sci Rep. 2015 Apr 22;5:9800
pubmed: 25902419
Nat Immunol. 2005 Mar;6(3):280-6
pubmed: 15685176
Oncotarget. 2016 Aug 30;7(35):56233-56240
pubmed: 27191652
Lung Cancer. 2020 Oct;148:1-11
pubmed: 32768804
Lung Cancer. 2019 Jan;127:153-163
pubmed: 30642544
Blood. 2006 Aug 1;108(3):812-20
pubmed: 16537807
J Immunother Cancer. 2019 Jul 10;7(1):173
pubmed: 31291995
Ann Oncol. 2016 Jan;27(1):147-53
pubmed: 26483045
Cancer Med. 2019 Apr;8(4):1467-1473
pubmed: 30848091
Lung Cancer. 2019 Nov;137:1-6
pubmed: 31518912
Sci Rep. 2018 Feb 7;8(1):2592
pubmed: 29416054
N Engl J Med. 2019 Nov 21;381(21):2020-2031
pubmed: 31562796
Front Immunol. 2018 Aug 03;9:1613
pubmed: 30123214
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Semin Cancer Biol. 2013 Jun;23(3):200-7
pubmed: 23403174
Oncotarget. 2017 May 31;8(57):97671-97682
pubmed: 29228642
Lancet Oncol. 2017 Sep;18(9):1182-1191
pubmed: 28734759
Cancer Res. 2019 Mar 15;79(6):1214-1225
pubmed: 30541742
Nat Immunol. 2018 Feb;19(2):108-119
pubmed: 29348500
Oncoimmunology. 2018 Apr 20;7(8):e1452581
pubmed: 30221046
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
Cell. 2020 Oct 15;183(2):363-376.e13
pubmed: 33007267
Eur J Cancer. 2019 Feb;108:88-96
pubmed: 30648633
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Sci Rep. 2016 Aug 24;6:31726
pubmed: 27553175
Sci Immunol. 2016 Aug;1(2):
pubmed: 28417112
J Immunol Res. 2014;2014:659294
pubmed: 25436215
EMBO Mol Med. 2019 Jul;11(7):e10293
pubmed: 31273938
J Exp Med. 2010 Sep 27;207(10):2187-94
pubmed: 20819927
J Immunol. 2011 Mar 1;186(5):2772-9
pubmed: 21263073
Ther Adv Med Oncol. 2019 Apr 16;11:1758835919839928
pubmed: 31019571
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
JAMA Oncol. 2018 Nov 1;4(11):1543-1552
pubmed: 30193240
JCI Insight. 2018 Dec 6;3(23):
pubmed: 30518691
ESMO Open. 2019 Aug 16;4(4):e000531
pubmed: 31555483
Lung Cancer. 2017 Apr;106:1-7
pubmed: 28285682
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Clin Immunol. 2000 Sep;96(3):230-5
pubmed: 10964541
Nature. 2019 Mar;567(7749):479-485
pubmed: 30894752
Oncoimmunology. 2019 Mar 27;8(6):e1593810
pubmed: 31069160
J Immunother Cancer. 2018 Nov 27;6(1):132
pubmed: 30482248
Oncotarget. 2017 Oct 7;8(61):103117-103128
pubmed: 29262550
Ther Clin Risk Manag. 2017 Oct 11;13:1363-1374
pubmed: 29066904
Nat Immunol. 2013 Dec;14(12):1212-8
pubmed: 24240160
Nat Rev Immunol. 2018 Mar;18(3):153-167
pubmed: 28990585
Proc Natl Acad Sci U S A. 2017 May 9;114(19):4993-4998
pubmed: 28446615
J Thorac Oncol. 2018 Aug;13(8):1113-1120
pubmed: 29704674